Liquid Biopsy and Multi-Cancer Early Detection | Diagnostics Market Intelligence

Description

List of Tables

The idea that a blood draw - or a urine sample - could find cancer before symptoms has organized a decade of diagnostics ambition, and Japan now hosts some of the field's most distinctive bets. Craif built a multi-cancer screen on urinary microRNA and distributes it through the country's dense health-check channel, raising a Series D in 2026 to scale. Sysmex's Inostics unit brings BEAMing digital PCR liquid biopsy to recurrence monitoring. A.D.A.M. Innovations partnered with SOPHiA Genetics to industrialize analysis. And Guardant Health set the reimbursement precedent that everything else cites: Guardant360 CDx, approved and paid under NHI, proved that a liquid biopsy test can clear Japan's regulatory and pricing machinery - at least when a drug label is attached.

The contested ground is the step beyond companion use: screening and multi-cancer early detection in apparently healthy people. The scientific questions are familiar - sensitivity in early-stage disease, false-positive management, the unresolved question of whether earlier detection by these tests changes outcomes - but Japan adds its own variables. The health-check system offers a distribution channel no other country matches. Self-pay testing operates in a regulatory space distinct from NHI-covered care. Physicians worry about confirmatory capacity if screening scales. And the pricing question looms: what Japan's C1/C2/C3 machinery would make of a population-scale screening claim is untested.

This report maps the Japanese liquid biopsy landscape across its three commercial zones: therapy selection, recurrence monitoring, and early detection. It profiles the platforms and companies - domestic and foreign - with their regulatory status and evidence positions, explains the technology families from methylation to microRNA in operational terms, and analyzes the channels: health checks, corporate programs, hospitals, and the boundaries of direct-to-consumer. Comparative chapters cover the US evidence programs, European positioning, and China's fast-moving MCED market.

The report serves precision-oncology investors, companion-diagnostics teams, health-check operators and their investors, and diagnostics strategists assessing where the category's next reimbursement precedents will be set.

Scope and Coverage: The report covers liquid biopsy in Japan across therapy selection, minimal residual disease and recurrence monitoring, and multi-cancer early detection: technologies, companies, evidence, regulation, reimbursement, and channels. Comparative coverage includes the United States, Europe, and China.

Report Highlights:

Platform profiles: Craif miSignal, Sysmex Inostics, A.D.A.M.-SOPHiA, and foreign entrants
Technology family analysis: ctDNA, methylation, fragmentomics, and microRNA
The Guardant360 CDx reimbursement precedent and what it does and does not establish
Health-check channel mechanics for distributing novel cancer tests
Evidence programs and regulatory status across use cases
Confirmatory-pathway and capacity analysis for screening claims

Product Code: JPH-055

Table of Content

1. Executive Summary

2. Liquid Biopsy and Multi-Cancer Early Detection: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

Craif (JP) - miSignal urine miRNA multi-cancer screening distributed through Japanese health-check channels; Series D financing (2026). Sysmex (JP) - Inostics BEAMing dPCR liquid biopsy and CRC recurrence-monitoring development. SOPHiA Genetics (CH) - partnership with A.D.A.M. Innovations for liquid-biopsy analysis in Japan. A.D.A.M. Innovations (JP) - genomic testing services and the SOPHiA Japan channel. Guardant Health (US) - Guardant360 CDx reimbursed in Japan and Shield CRC blood screening. Natera (US) - Signatera MRD franchise and Japan expansion following PMDA approval. GRAIL (US) - Galleri MCED test with PATHFINDER 2 and NHS-Galleri evidence generation. Exact Sciences (US) - Cancerguard MCED blood test launched (2025). Tempus (US) - xF liquid-biopsy sequencing and data-enabled oncology testing. Burning Rock (CN) - OverC MCED and tumor-informed MRD assays in China. Genecast (CN) - ctDNA MRD and liquid-biopsy assays in China. Hirotsu Bio Science (JP) - N-NOSE nematode-based urine screening sold through Japanese consumer channels.

Product Code: JPH-055

List of Tables

Table 1. Liquid biopsy analyte taxonomy: ctDNA, methylation, microRNA, and proteins
Table 2. Tumor-informed versus agnostic liquid biopsy design
Table 3. Methylation-based multi-cancer detection: technical principles
Table 4. Fragmentomics and multiomics approaches
Table 5. Urinary microRNA as a screening analyte
Table 6. Digital PCR versus NGS detection architectures
Table 7. Analytical validation frameworks for early-detection tests
Table 8. Craif miSignal platform design and indication scope
Table 9. Craif distribution through health-check channels
Table 10. Craif Series D financing (2026) and investor base
Table 11. Sysmex Inostics BEAMing digital PCR platform
Table 12. Sysmex colorectal recurrence monitoring development program
Table 13. A.D.A.M. Innovations and SOPHiA Genetics partnership structure
Table 14. Guardant Health portfolio positioning in Japan
Table 15. Guardant360 CDx approval and reimbursement history in Japan
Table 16. GRAIL Galleri development and availability status relative to Japan
Table 17. Exact Sciences and Freenome early-detection programs
Table 18. Multi-cancer early detection clinical evidence requirements
Table 19. PATHFINDER study design
Table 20. NHS-Galleri trial design
Table 21. Craif clinical validation study program
Table 22. Sensitivity by stage: interpretive frameworks
Table 23. Specificity and false-positive management pathways
Table 24. Tissue-of-origin localization performance frameworks
Table 25. Interval cancer and lead-time considerations
Table 26. Japanese population evidence base for liquid biopsy
Table 27. PMDA pathway options for early-detection claims
Table 28. NHI price formation for liquid biopsy categories
Table 29. Self-pay testing regulatory space in Japan
Table 30. Boundaries between consumer testing and medical practice
Table 31. Laboratory testing regulation for service-based assays
Table 32. Insurance coverage of confirmatory diagnostics after positive screens
Table 33. Guideline positions on multi-cancer testing in Japan
Table 34. Health-check (kenshin) channel integration for novel tests
Table 35. Corporate health program adoption of cancer screening tests
Table 36. Clinic and hospital distribution structures
Table 37. Direct-to-consumer boundary management in Japan
Table 38. Physician counseling requirements for novel screening tests
Table 39. Confirmatory diagnostic capacity after positive multi-cancer tests
Table 40. Patient communication and consent frameworks
Table 41. Adoption barriers in Japanese clinical practice
Table 42. Single-cancer versus multi-cancer test positioning
Table 43. Colorectal screening adjacency of blood-based tests
Table 44. MRD and recurrence monitoring convergence with screening platforms
Table 45. Pharmaceutical partnerships in liquid biopsy
Table 46. Data and AI roles in multiomics interpretation
Table 47. Investment activity in Japanese liquid biopsy
Table 48. Regulatory watchlist for liquid biopsy in Japan
Table 49. Adoption scenario framework
Table 50. Report methodology and evidence sources

List of Figures

Figure 1. Liquid biopsy analyte taxonomy map
Figure 2. Tumor-informed versus agnostic design schematic
Figure 3. Methylation detection principle diagram
Figure 4. Fragmentomics approach schematic
Figure 5. Urinary microRNA workflow
Figure 6. Digital PCR versus NGS architecture comparison
Figure 7. Validation framework for early-detection tests
Figure 8. miSignal platform workflow
Figure 9. Craif health-check distribution map
Figure 10. Craif financing timeline
Figure 11. BEAMing digital PCR workflow
Figure 12. Sysmex recurrence monitoring program structure
Figure 13. A.D.A.M.-SOPHiA partnership structure map
Figure 14. Guardant Health Japan portfolio map
Figure 15. Guardant360 CDx approval and reimbursement timeline
Figure 16. Galleri development status map
Figure 17. Early-detection program landscape
Figure 18. MCED evidence requirement hierarchy
Figure 19. PATHFINDER study schema
Figure 20. NHS-Galleri trial schema
Figure 21. Craif validation program map
Figure 22. Stage-sensitivity interpretive framework
Figure 23. False-positive management pathway
Figure 24. Tissue-of-origin localization framework
Figure 25. Lead-time and interval cancer schematic
Figure 26. Japanese evidence base map
Figure 27. PMDA pathway options for screening claims
Figure 28. NHI price formation flow for liquid biopsy
Figure 29. Self-pay regulatory space map
Figure 30. Consumer-testing boundary framework
Figure 31. Laboratory service regulation map
Figure 32. Confirmatory coverage pathway
Figure 33. Guideline position map for MCED in Japan
Figure 34. Health-check channel integration flow
Figure 35. Corporate program adoption pathway
Figure 36. Clinic and hospital distribution map
Figure 37. Direct-to-consumer boundary map
Figure 38. Counseling requirement framework
Figure 39. Confirmatory capacity analysis map
Figure 40. Consent and communication framework
Figure 41. Adoption barrier map
Figure 42. Single- versus multi-cancer positioning matrix
Figure 43. Blood-based CRC screening adjacency map
Figure 44. Screening-monitoring convergence schematic
Figure 45. Pharma partnership structure map
Figure 46. Multiomics data architecture
Figure 47. Investment activity timeline
Figure 48. Regulatory watchlist map
Figure 49. Adoption scenario tree
Figure 50. Report methodology schematic

Liquid Biopsy and Multi-Cancer Early Detection | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Liquid Biopsy and Multi-Cancer Early Detection: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures